Benefits
Acute ischemic stroke neurological function (PMC12417717 META-ANALYSIS 2024)
PMC12417717 (2024) — META-ANALYSIS following PRISMA guidelines. Risk of bias assessed via RoB 2.0; evidence quality graded via GRADE. Publication bias evaluated via funnel plots. RESULTS: Lumbrokinase IMPROVES NEUROLOGICAL FUNCTION and REDUCES LABORATORY MARKERS of THROMBOSIS in patients with ACUTE ISCHEMIC STROKE when used ALONGSIDE supportive care. Important: ALTEPLASE remains standard thrombolytic therapy; lumbrokinase positioned as ADJUNCT in low-resource settings where alteplase availability limited. Foundational meta-analytic evidence.
Secondary ischemic stroke prevention (Cao 2013 multicenter RCT)
Cao YJ, Zhang X, Wang WH, Zhai WQ, Qian JF, Wang JS et al. 2013 (Chin Med J 126:4060-4065) — Oral fibrinogen-depleting agent lumbrokinase for SECONDARY ISCHEMIC STROKE PREVENTION. MULTICENTER, RANDOMIZED, parallel-group, controlled clinical trial. Mechanism: fibrinogen depletion + fibrinolytic activity. Foundational large-trial Chinese evidence supporting secondary stroke prevention indication.
Cerebral infarct hemostasis modulation (Jin et al. 51 subjects)
Jin et al. — 51 cerebral infarct subjects given 3×400 mg lumbrokinase (n=31) or control (n=20) for 28 days. RESULTS: KAOLIN PARTIAL THROMBOPLASTIN TIME (KPTT) PROLONGED. tPA ACTIVITY + D-DIMER LEVEL INCREASE. FIBRINOGEN DECREASED significantly. Mechanism: oral antithrombotic + fibrinolytic activity via inhibition of coagulation intrinsic pathway + activation of fibrinolytic pathway by INCREASING tPA activity. Foundational hemostasis mechanism evidence.
Diabetic foot ulcer healing (Rey 28 subjects)
Rey et al. — 28 diabetic foot ulcer subjects given 3×500 mg lumbrokinase per day (n=14) for 7 days vs placebo. Treatment group showed improvements in fibrinolytic activity. Mechanism: fibrin matrix dissolution allowing improved tissue perfusion. Important EMERGING APPLICATION beyond stroke.
DLBS1033 hemostasis healthy volunteers (NCT01694537)
NCT01694537 — DLBS1033 (Indonesian commercial form of lumbrokinase) clinical trial in HEALTHY VOLUNTEERS evaluating effects on human fibrinolytic + coagulation systems. DLBS1033 contains lumbrokinase consisting of 6 isoenzyme serine proteases. In vitro mechanism: FIBRINOGENOLYTIC ACTIVITIES on fibrinogen α, β, γ chains; DECREASED PLATELET AGGREGATION; PROLONGED CLOTTING TIME. Foundational human PK/PD evidence.
DLBS1033 acute ischemic stroke RCT (PMC8049819)
PMC8049819 — DLBS1033 RCT in acute ischemic stroke patients (Bethesda Hospital Yogyakarta, Indonesia, 2019-2020). Add-on therapy to standard treatment. Important: established lumbrokinase efficacy in non-Chinese population — supports geographic generalizability beyond historical Chinese clinical trial dominance.
Sirt1 activation cardioprotection (Wang 2018)
Wang YH, Li SA, Huang CH, Su HH, Chen YH, Chang JT, Huang SS 2018 (Front Pharmacol 9:636) — Post-ischemic treatment with lumbrokinase ACTIVATES SIRT1 → PROTECTS against MYOCARDIAL ISCHEMIA-REPERFUSION INJURY. Wang 2016 (J Mol Cell Cardiol 99:113-122) — lumbrokinase attenuates myocardial ischemia-reperfusion via TLR4 signaling inhibition. PRECLINICAL cardioprotective mechanism evidence.
Mechanism of action
Direct fibrinolysis (FIBRIN-SPECIFIC)
Lumbrokinase DIRECTLY DISSOLVES FIBRIN — primary mechanism. Distinguishing feature: HIGHLY FIBRIN-SPECIFIC (vs nattokinase broader activity). Acts SELECTIVELY in presence of fibrin, may reduce likelihood of interfering with normal clotting processes. Foundational fibrinolytic mechanism.
Indirect fibrinolysis via tPA + plasminogen-to-plasmin
Promotes PLASMINOGEN-TO-PLASMIN CONVERSION via INCREASED tPA ACTIVITY. Mechanism: lumbrokinase increases native tPA activity, dissolving fibrin clots. Important secondary fibrinolytic mechanism complementary to direct fibrinolysis.
Six serine-protease enzyme group (Cho 2004 characterization)
Cho 2004 (J Biochem Mol Biol 37:199-205) — characterization of SIX fibrinolytic serine-proteases from L. rubellus collectively named lumbrokinase. Mihara 1991 PMID 1960890 foundational original characterization. Distinct compositional profile (abundant asparagine/aspartic acid).
Higher thermal stability + alkali resistance
Lumbrokinase has SUPERIOR THERMAL STABILITY + ALKALI RESISTANCE compared to urokinase + streptokinase. Mechanism: appropriate for oral administration (resists gastric environment better than typical fibrinolytics). Practical pharmaceutical advantage.
Does NOT convert plasminogen to plasmin directly
Distinguishing feature: lumbrokinase does NOT directly convert plasminogen to plasmin (unlike urokinase, streptokinase, tPA). Reduces risk of systemic plasmin activation + bleeding. Supports HIGHER FIBRIN-SPECIFICITY safety profile.
TLR4 signaling inhibition (preclinical cardioprotective)
Wang 2016 — lumbrokinase attenuates myocardial ischemia-reperfusion injury via TLR4 signaling inhibition. Anti-inflammatory mechanism distinct from fibrinolytic activity. Preclinical evidence.
Sirt1 activation (preclinical cardioprotective)
Wang 2018 — post-ischemic lumbrokinase ACTIVATES SIRT1 → cardioprotection. Mechanism extends beyond fibrinolytic activity to cellular stress response. Preclinical evidence.
Clinical trials
Systematic review + meta-analysis (PMC12417717, 2024). PRISMA guidelines. Risk of bias via RoB 2.0; evidence quality via GRADE; publication bias via funnel plots. Database search through July 2024.
Pooled analysis of randomized controlled trials of lumbrokinase as adjunct treatment for acute ischemic stroke alongside supportive care.
LUMBROKINASE IMPROVES NEUROLOGICAL FUNCTION + REDUCES LABORATORY MARKERS OF THROMBOSIS in patients with ACUTE ISCHEMIC STROKE alongside supportive care. Important context: ALTEPLASE remains standard thrombolytic therapy; lumbrokinase as ADJUNCT in low-resource settings with limited alteplase availability. Foundational meta-analytic evidence — methodologically rigorous (PRISMA + GRADE).
Multicenter randomized parallel-group controlled clinical trial (Cao YJ, Zhang X, Wang WH, Zhai WQ, Qian JF, Wang JS et al. 2013, Chin Med J 126:4060-4065).
Patients with prior ischemic stroke. Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention vs control.
FOUNDATIONAL MULTICENTER RCT supporting SECONDARY ISCHEMIC STROKE PREVENTION indication. Mechanism: fibrinogen depletion + fibrinolytic activity reducing recurrent stroke risk. Important Chinese-population evidence base — methodological limitations typical of Chinese trials of this era.
Clinical trial in cerebral infarct subjects.
51 cerebral infarct subjects. 3×400 mg lumbrokinase (n=31) or control (n=20) for 28 days. Multiple hemostasis parameters measured.
KPTT (KAOLIN PARTIAL THROMBOPLASTIN TIME) PROLONGED. tPA ACTIVITY + D-DIMER LEVEL INCREASED. FIBRINOGEN DECREASED significantly. Mechanism: oral antithrombotic + fibrinolytic activity via inhibition of coagulation intrinsic pathway + activation of fibrinolytic pathway. Foundational hemostasis mechanism evidence in stroke patients.
About this ingredient
LUMBROKINASE refers to a GROUP OF SIX (6) FIBRINOLYTIC SERINE-PROTEASE ENZYMES extracted from the EARTHWORM Lumbricus rubellus. Used in TRADITIONAL CHINESE MEDICINE for centuries as 'di long' (earth dragon) for various circulatory conditions. ENZYMOLOGICAL CHARACTERIZATION: MIHARA 1991 PMID 1960890 (Jpn J Physiol 41:461-472) FOUNDATIONAL characterization paper — novel fibrinolytic enzymes named collectively as Lumbrokinase. CHO 2004 (J Biochem Mol Biol 37:199-205) — purification + characterization of 6 fibrinolytic serine-proteases. Distinct compositional profile: abundant asparagine/aspartic acid + minimal proline/lysine vs typical serine proteases. CLINICAL EVIDENCE: PMC12417717 (2024) META-ANALYSIS following PRISMA guidelines + GRADE evidence quality assessment + RoB 2.0 risk of bias — lumbrokinase IMPROVES NEUROLOGICAL FUNCTION + REDUCES LABORATORY MARKERS OF THROMBOSIS in ACUTE ISCHEMIC STROKE alongside supportive care. CAO 2013 (Chin Med J 126:4060-4065) MULTICENTER RANDOMIZED PARALLEL-GROUP CONTROLLED CLINICAL TRIAL for SECONDARY ISCHEMIC STROKE PREVENTION via oral fibrinogen-depleting agent. JIN ET AL 51 cerebral infarct subjects 3×400 mg/day × 28 days — KPTT prolonged, tPA activity + D-dimer increased, fibrinogen decreased significantly. REY ET AL 28 DIABETIC FOOT ULCER subjects 3×500 mg/day × 7 days — fibrinolytic activity improvements. NCT01694537 DLBS1033 (Indonesian commercial form) HEALTHY VOLUNTEER hemostasis trial — fibrinogenolytic activities on fibrinogen α/β/γ chains, decreased platelet aggregation, prolonged clotting time. PMC8049819 DLBS1033 ACUTE ISCHEMIC STROKE RCT add-on therapy at Bethesda Hospital Yogyakarta Indonesia. WANG 2018 (Front Pharmacol 9:636) Sirt1 activation post-ischemic CARDIOPROTECTION (preclinical). WANG 2016 (J Mol Cell Cardiol 99:113-122) TLR4 signaling inhibition cardioprotective (preclinical). PMC6013847 endoplasmic reticulum stress regulation in ischemic stroke (preclinical).
MECHANISMS: DIRECT FIBRINOLYSIS (FIBRIN-SPECIFIC — distinguishing from nattokinase which has broader activity); INDIRECT FIBRINOLYSIS via tPA + plasminogen-to-plasmin conversion enhancement; HIGHER THERMAL STABILITY + ALKALI RESISTANCE vs urokinase/streptokinase/tPA (oral administration suitability); does NOT directly convert plasminogen to plasmin (reduces systemic plasmin activation risk); TLR4 signaling inhibition (preclinical anti-inflammatory cardioprotective); Sirt1 activation (preclinical cardioprotective). EVIDENCE: 2/5 reflects: (1) PMC12417717 META-ANALYSIS PIVOTAL with PRISMA + GRADE rigor — foundational acute ischemic stroke evidence, (2) CAO 2013 MULTICENTER RCT for secondary stroke prevention, (3) JIN ET AL hemostasis mechanism evidence, (4) REY ET AL diabetic foot ulcer emerging application, (5) DLBS1033 Indonesian non-Chinese geographic generalizability evidence, (6) WELL-CHARACTERIZED fibrin-specific fibrinolytic mechanism distinct from nattokinase, (7) 6-enzyme group Cho 2004 + Mihara 1991 characterization, (8) HONEST LIMITATIONS — most evidence from China with small samples + methodological limitations, (9) LIMITED long-term safety data beyond 28-day trials, (10) NO HEAD-TO-HEAD RCTs vs alteplase or other established fibrinolytics, (11) preclinical cardioprotective + neuroprotective mechanisms not yet translated to clinical trial endpoints. SAFETY: Generally favorable bleeding profile vs systemic fibrinolytics due to fibrin-specificity; long-term safety + bleeding event surveillance limited. Best positioned as: (a) ACUTE ISCHEMIC STROKE ADJUNCT in low-resource settings where alteplase unavailable (PMC12417717 meta-analysis evidence — NOT replacement for alteplase), (b) SECONDARY ISCHEMIC STROKE PREVENTION (Cao 2013 evidence — discuss with neurologist), (c) CARDIOVASCULAR HEMOSTASIS support adjunct, (d) DIABETIC FOOT ULCER adjunct (Rey emerging evidence), (e) ALTERNATIVE/COMPLEMENTARY to nattokinase for those wanting fibrin-specific fibrinolytic without nattokinase broader activity, (f) NOT recommended without physician supervision in cardiovascular disease, (g) BLEEDING DISORDERS, RECENT SURGERY, ANTICOAGULANT USERS: AVOID, (h) PREGNANCY: AVOID, (i) ETHICAL/RELIGIOUS context: earthworm-derived ingredient may concern vegetarians/vegans + certain religious practices, (j) lower-evidence than nattokinase per current evidence base — most clinical trials Chinese with methodological limitations. Honest framing: Lumbrokinase has GROWING but LIMITED clinical evidence — PMC12417717 2024 meta-analysis with PRISMA + GRADE methodology is genuinely rigorous evidence of acute ischemic stroke benefit alongside supportive care. Cao 2013 multicenter RCT supports secondary stroke prevention. Mihara 1991 + Cho 2004 enzymological characterization is foundational.
CRITICAL HONEST LIMITATIONS: most clinical trials from China with small samples + methodological limitations — Western/Indonesian DLBS1033 trials add geographic generalizability but evidence base remains thin compared to alteplase or warfarin/DOAC anticoagulants. NO HEAD-TO-HEAD trials vs established treatments. Long-term safety + bleeding event surveillance limited. Not first-line cardiovascular preventive therapy. Reasonable cardiovascular adjunct for those wanting fibrin-specific fibrinolytic enzyme — but anticoagulant users + bleeding disorder patients should AVOID. Distinguished from nattokinase by fibrin-specificity; broader nattokinase activity may suit different applications. Position as adjunctive cardiovascular support rather than primary therapy.